* Bioventus Inc BVS.OQ BVS.O is expected to show a rise
in
quarterly revenue when it reports results on August 11.
* The Durham North Carolina-based company is expected to
report
a 26.0% increase in revenue to $138.332 million from $109.82
million a year ago, according to the mean estimate from 4
analysts, based on Refinitiv data.
* Refinitiv's mean analyst estimate for Bioventus Inc is
for
earnings of 16 cents per share. For the same quarter last year,
the company reported earnings of 16 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Bioventus
Inc is
$16.5, above its last closing price of $8.55.
* Previous quarterly performance (using preferred earnings
measure
in US dollars).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Mar. 31 2022 0.05 0.05 0.04 Missed -16.7
Dec. 31 2022 0.17 0.18 0.26 Beat 46.5
Sep. 30 2021 0.14 0.14 0.25 Beat 78.6
Jun. 30 2021 0.10 0.14 0.16 Beat 16.4
Mar. 0.10 0.10 0.15 Beat 57.9
31 2021
Dec. 31 2020 0.23 0.23 2.32 Beat 908.7
This summary was machine generated August 9 at 18:34 GMT. All
figures in US dollars unless otherwise stated